For research use only. Not for therapeutic Use.
Cefoxitin Sodium（Cat No.:I003218）is a broad-spectrum, semi-synthetic cephamycin antibiotic, effective against both Gram-positive and Gram-negative bacteria. It is commonly used in the treatment of infections, including intra-abdominal infections, respiratory tract infections, and surgical prophylaxis. As a beta-lactam antibiotic, Cefoxitin Sodium works by inhibiting bacterial cell wall synthesis, leading to cell death. This compound is resistant to many beta-lactamases, providing enhanced activity against certain resistant organisms. Its sodium salt form ensures proper solubility for intravenous administration, making it a reliable choice for treating various bacterial infections in clinical settings.
| Catalog Number | I003218 |
| CAS Number | 33564-30-6 |
| Synonyms | (6R,7S)-3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosodium salt |
| Molecular Formula | C16H16N3O7S2 • Na |
| Purity | ≥95% |
| Target | Bacterial |
| Solubility | DMSO:32mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | sodium;(6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| InChI | InChI=1S/C16H17N3O7S2.Na/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19;/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22);/q;+1/p-1/t14-,16+;/m1./s1 |
| InChIKey | GNWUOVJNSFPWDD-XMZRARIVSA-M |
| SMILES | CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)[O-])NC(=O)CC3=CC=CS3.[Na+] |
| Reference | </br>1:Antimicrobial Hyaluronic Acid-Cefoxitin Sodium Thin Films Produced by Electrospraying. Ahire JJ, Dicks LM.Curr Microbiol. 2016 Aug;73(2):236-41. doi: 10.1007/s00284-016-1057-1. Epub 2016 May 5. PMID: 27146506 </br>2:Investigation on the effect of fluorescence quenching of bovine serum albumin by cefoxitin sodium using fluorescence spectroscopy and synchronous fluorescence spectroscopy. Li G, Liu BS, Zhang Q, Han R.Luminescence. 2016 Aug;31(5):1054-62. doi: 10.1002/bio.3071. Epub 2015 Dec 17. PMID: 26678839 </br>3:Microbiological assay for cefoxitin sodium in dosage form. Salgado HR, Tozo GC.J AOAC Int. 2007 Mar-Apr;90(2):452-5. PMID: 17474516 </br>4:Stability of Ranitidine Hydrochloride with Cefazolin Sodium, Cefbuperazone Sodium, Cefoxitin Sodium and Cephalothin Sodium during Simulated Y-Site Administration. Inagaki K, Miyamoto Y, Kurata N, Nakane S, Gill MA, Nishida M.Int J Pharm Compd. 2000 Mar-Apr;4(2):150-3. PMID: 23985950 </br>5:Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs. Stiles ML, Tu YH, Allen LV Jr.Am J Hosp Pharm. 1989 Jul;46(7):1408-12. PMID: 2667354 </br>6:Absorption enhancement of rectally infused cefoxitin sodium by medium-chain fatty acids in conscious rats: concentration-effect relationship. van Hoogdalem EJ, Hardens MA, de Boer AG, Breimer DD.Pharm Res. 1988 Jul;5(7):453-6. PMID: 3247317 </br>7:Cost-effectiveness of cefonicid sodium versus cefoxitin sodium for the prevention of postoperative infections after nonelective cesarean section. Briggs GG, Moore BR, Bahado-Singh R, Lange S, Bogh P, Garite TJ.Clin Pharm. 1987 Sep;6(9):718-21. No abstract available. PMID: 3119278 </br>8:A variant of Hoigne/’s syndrome following intramuscular cefoxitin sodium? Rockney R.Am J Dis Child. 1987 May;141(5):475-6. No abstract available. PMID: 3578148 </br>9:Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitin sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions. Bosso JA, Townsend RJ.Am J Hosp Pharm. 1985 Oct;42(10):2211-4. PMID: 3864367 </br>10:[Treatment and prevention of infections with cefoxitin sodium in patients with biliary tract infections and obstructive jaundice]. Fuji T, Harima K, Ariyama S, Maetani N, Nagatomi Y, Kawashima M, Aibe T, Amano H, Asagami F, Goto T, Kawamura S, Takemoto T.Jpn J Antibiot. 1982 Aug;35(8):1987-92. Japanese. PMID: 7154246 |
